Left ventricular hypertrophy is present in one-half of newly-diagnosed peripheral arterial disease patients

Journal of Hypertension

Volumn 25, Issue 2, 2007, Pages 463-469

  Wright, Gary A ^a   Ang, Donald S C ^a   Stonebridge, Peter A ^a   Belch, Jill J F ^a   Struthers, Allan D ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Hypertension; Hypertrophy; Myocardium; Peripheral vascular disease; Ventricles

Indexed keywords

ADULT; AGED; ARTERY DISEASE; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BODY SURFACE; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; HEART DEATH; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART MUSCLE; HEART VENTRICLE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; SCREENING;

EID: 33846110447     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328010d64b     Document Type: Article

References (21)

1. Belch JJF, Topol EJ, Agnelli G, Bertrand M, Califf RM, Clement DL, et al. Prevention of atherothrombotic disease network. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 2003; 163:884-892.
2. Liao Y, Cooper RS, McGee DL, Mensah GA, Ghali JK. The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA 1995; 273:1592-1597.
3. Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 1988; 108:7-13.
4. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322:1561-1566.
5. Cooper RS, Simmons BE, Castaner A, Santhanam V, Ghali J, Mar M. Left ventricular hypertrophy is associated with worse survival independent of ventricular function and number of coronary arteries severely narrowed. Am J Cardiol 1990; 65:441-445.
6. Ghali JK, Liao Y, Simmons B, Castaner A, Cao G, Cooper RS. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med 1992; 117:831-836.
7. Dawson A, Morris AD, Struthers AD. The epidemiology of LVH in type 2 diabetes mellitus. Diabetologia 2005; 48:1971-1979.
8. Sukhija R, Aronow WS, Kakar P, Levy JA, Lehrman SG, Babu S. Prevalence of echo LVH in persons with systemic hypertension, coronary artery disease and PAD and in persons with systemic hypertension, CAD and no PAD. Am J Cardiol 2005; 96:825-826.
9. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97:48-54.
10. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001; 141:334-341.
11. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995; 13:1091-1095.
12. Mancini GBJ, Dahlof B, Diez J. Surrogate markers for cardiovascular disease. Structural markers. Circulation 2004; 109 (Suppl IV): 22-30.
13. JBS2. Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91 (Suppl V):V22.
14. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of LVH: companion to necropsy findings. Am J Cardiol 1986; 57:450-458.
15. de Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH. Effect of growth on variability of left ventricular mass: allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol 1995; 25:1056-1062.
16. Devereux RB, Roman MJ, de Simone G, O'Grady MJ, Paranicas M, Yeh JL, et al. Relations of left ventricular mass to demographic and hemodynamic variables in American Indians: the Strong Heart Study. Circulation 1997; 96:1416-1423.
17. Mancia G, Carugo S, Grassi G, Lanzarotti A, Schiavina R, Cesana G, Sega R, for the PAMELA study. Prevalence of LVH in hypertensive patients without and with BP control: data from the PAMELA population. Hypertension 2002; 39:744-749.
18. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003; 108:1831-1838.
19. Cooper GJ, Phillips AR, Choong SY, Leonard BL, Crossman DJ, Brunton DH, et al. Regeneration of the heart in diabetes by selective copper chelation. Diabetes 2004; 53:2501-2508.
20. Liebson PR, Grandits GA, Dianzumba S, Prineas RJ, Grimm RH Jr, Neaton JD, Stamler J. Comparison of five antihypertensive monotherapies and placebo for changes in LV mass in patients receiving nutritional-hygienic therapy in the TOMHS study. Circulation 1995; 91:698-706.
21. Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia is an impediment to achieving the healthy people 2010 blood pressure control goals. Hypertension 2006; 47:345-351.